TLRY - Tilray, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
106.77
-3.71 (-3.36%)
At close: 4:00PM EST

101.25 -5.52 (-5.17%)
Pre-Market: 8:27AM EST

Stock chart is not supported by your current browser
Previous Close110.48
Open110.46
Bid101.11 x 3000
Ask102.50 x 1100
Day's Range102.30 - 110.95
52 Week Range20.10 - 300.00
Volume1,711,673
Avg. Volume8,318,773
Market Cap9.947B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.43
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est140.00
Trade prices are not sourced from all markets
  • Trulieve Surpassed Analysts’ Q3 Revenue Estimates
    Market Realist20 minutes ago

    Trulieve Surpassed Analysts’ Q3 Revenue Estimates

    The company reported revenues of $28.3 million during the third quarter of 2018 as compared to Wall Street analyst estimates of $26.6 million (or 35.1 million Canadian dollars) during the quarter. The below chart compares revenues for Trulieve since the third quarter of 2017. The Horizons Marijuana Life Sciences Index ETF (HMMJ) holds 11.8% of its total investments in Tilray (TLRY), 0.5% in WeedMD (WMD) (WDDMF), and 1.0% in Vivo Cannabis (VVCIF).

  • Marijuana Earnings Wrap-Up: Cannabis Stock Winners and Losers
    Motley Fool16 hours ago

    Marijuana Earnings Wrap-Up: Cannabis Stock Winners and Losers

    Investors didn't get the big pops they'd hoped to see.

  • Top and Flop ETFs of Last Week
    Zacks20 hours ago

    Top and Flop ETFs of Last Week

    Inside the winning and losing ETFs of the last week.

  • Can These 3 Pummeled Pot Stocks Recover?
    Motley Fool23 hours ago

    Can These 3 Pummeled Pot Stocks Recover?

    Replacing billions lost in recent weeks won't be easy for these Canadian cannabis producers.

  • MedMen’s Valuation versus Its Peers’
    Market Realistyesterday

    MedMen’s Valuation versus Its Peers’

    MedMen Enterprises (MMNFF) holds 19 licensed cannabis facilities for cultivation, manufacturing, and marketing cannabis as a consumer product. This article compares MedMen’s (MMNFF) valuation with its peers’, including Tilray (TLRY), CannaRoyalty (OH), and Maricann (MRRCF).

  • Cannabis Stocks Ended Last Week in Negative Territory
    Market Realistyesterday

    Cannabis Stocks Ended Last Week in Negative Territory

    The cannabis sector ended in negative territory last week. The Horizons Marijuana Life Sciences ETF (HMMJ) fell ~6.2%, and the ETFMG Alternative Harvest ETF (MJ) fell 5.8% during the period. Most cannabis stocks also ended in the negative territory.

  • MedMen’s Territory Expansion: The Recent Agreements
    Market Realistyesterday

    MedMen’s Territory Expansion: The Recent Agreements

    MedMen (MMNFF) has entered into agreements with different companies to expand its footprint. We outline a few of the recent agreements below.

  • ACCESSWIREyesterday

    4 Marijuana Stocks To Watch During Thanksgiving Week

    / This month marijuana stocks have been very active. As of November 7, US Attorney General Jeff Sessions is out and an interim AG is in. This all occurred following Canada’s full legalization of recreational and medicinal cannabis.

  • Best Big Marijuana Stock: Aurora Cannabis, Canopy Growth, or Tilray?
    Motley Fool2 days ago

    Best Big Marijuana Stock: Aurora Cannabis, Canopy Growth, or Tilray?

    They're the biggest. But which is the best?

  • 4 Prominent Marijuana Earnings Season Trends
    Motley Fool3 days ago

    4 Prominent Marijuana Earnings Season Trends

    Surprise! Pot stock operating results actually matter now.

  • 2 Reasons Pot Stocks Could Plunge in January
    Motley Fool3 days ago

    2 Reasons Pot Stocks Could Plunge in January

    It may be a buzzkill beginning to the New Year.

  • 3 Bear-Busting Stocks to Buy, Including Tilray
    InvestorPlace4 days ago

    3 Bear-Busting Stocks to Buy, Including Tilray

    The good news is — if you’re an investor that desires price volatility working for you rather than against you — Under Armour (NYSE:UAA), Chipotle (NYSE:CMG) and Tilray (NASDAQ:TLRY) are bear-busting stocks to buy today. Toss in decent, but not over-the-top short interest to help fuel the upside and the peace of mind that comes with owning brand recognition and a large-cap company—and the case for UAA, CMG and TLRY only grows stronger. Click to Enlarge The first of our large-cap stocks to buy is Under Armour.

  • Trulieve to Announce Q3 Earnings on November 19!
    Market Realist4 days ago

    Trulieve to Announce Q3 Earnings on November 19!

    Trulieve Cannabis Corp (TCNNF) is a licensed medical cannabis company set to release its Q3 2018 earnings on November 19 at 10:00 AM ET. Analysts expect Trulieve to report revenues of 35.1 million Canadian dollars for the third quarter of 2018. Trulieve is a vertically integrated cannabis company involved in the cultivation, production, and commercialization of cannabis products in the State of Florida.

  • Why Citron’s Andrew Left Is Shorting Cannabis Stocks
    Market Realist4 days ago

    Why Citron’s Andrew Left Is Shorting Cannabis Stocks

    Cannabis stocks have made several investors wary because of their high level of volatility. Earlier this week, some of the companies that reported earnings such as Canopy Growth (WEED), Tilray (TLRY), and Aurora Cannabis (ACB) (ACBFF) missed analysts’ estimates by a large margin, and the stocks got hammered. In an interview with CNBC, Andrew Left of Citron Research was largely pessimistic on the Canadian cannabis industry and expects that cannabis stocks will fall in the near term.

  • Tilray's Q3 Report Clearly Shows That It's Not Worth $10 Billion
    Motley Fool4 days ago

    Tilray's Q3 Report Clearly Shows That It's Not Worth $10 Billion

    This high-flying marijuana stock's operating results raise a number of red flags.

  • Why Tilray's Still Up Over 400% in 2018 to Date
    Motley Fool4 days ago

    Why Tilray's Still Up Over 400% in 2018 to Date

    Despite a big swoon, the recent cannabis IPO still has strong believers.

  • Jim Cramer’s Recommendations in the Cannabis Industry
    Market Realist4 days ago

    Jim Cramer’s Recommendations in the Cannabis Industry

    On November 15, the widely followed host of Mad Money on CNBC, Jim Cramer, gave his opinions on the cannabis industry. Cramer pointed investors to Canopy Growth (WEED) (CGC), the Canadian cannabis (HMMJ) giant, because of its backing from Constellation Brands as a result of the latter’s $4 billion investment.

  • Which Marijuana Stock Won Earnings Week -- Aurora Cannabis, Canopy Growth, Cronos Group, or Tilray?
    Motley Fool4 days ago

    Which Marijuana Stock Won Earnings Week -- Aurora Cannabis, Canopy Growth, Cronos Group, or Tilray?

    There was a flurry of earnings releases this week from leaders of the Canadian cannabis industry. Here are the winners and losers.

  • TheStreet.com4 days ago

    Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

    The big financial institutions are negative right now and that means any positive light is going to be bent into negative light, Jim Cramer told his Mad Money viewers on Thursday evening. Right now, all the talk is about "late cycle," as in, we're in the late stage of the economic cycle. The economy can handle the initial rate hikes from the Federal Reserve, because rates were so low to begin with, Cramer reasoned.

  • Why Arena Pharmaceuticals, Smart & Final Stores, and Tilray Jumped Today
    Motley Fool5 days ago

    Why Arena Pharmaceuticals, Smart & Final Stores, and Tilray Jumped Today

    Smart strategic moves helped these stocks gain ground.

  • TheStreet.com5 days ago

    Cowen Says Tilray Is Still a Buy Despite Spate of Underwhelming Pot Earnings

    is still a buy, according to analysts at Cowen, who lowered the company's price target to $150 a share from $172, while maintaining their "outperform" rating. Shares of Tilray were rising about 6% on Thursday. Tilray was part of a spate of cannabis company earnings releases this week, reporting revenue of $10 million that was slightly below estimates, which sent the stock tumbling following the release.

  • Barrons.com5 days ago

    Marijuana Companies’ Sales Disappoint, and the Stocks Are Plunging

    Canada’s pot industry reported its latest financial results this week, and investors think the September quarter was a bust. The U.S.-listed stocks of Canadian producers (WEED) (ticker: CGC), (ACB) (ACB), and (TLRY) (TLRY) are sinking. Since Monday, when Aurora reported a 333% sales jump from its year-ago quarter, its New York Stock Exchange–listed stock has slipped 18%, to US$6.16.

  • ACCESSWIRE5 days ago

    4 Marijuana Stocks Investors Should Know About Before 2019

    The global legal marijuana market is expected to reach USD 146.4 billion by end of 2025, according to a new report by Grand View Research, Inc. Growing adoption of marijuana in several medical applications such as cancer, mental disorders, chronic pain, and others is expected to propel revenue growth in the near future. As the industry continues to gain the attention of early investors, companies like Premier Health Group, Inc. (PHGRF) (PHGI), Aurora Cannabis (ACB)(ACB), New Age Beverages (NBEV), and Tilray (TLRY) are working toward new sector growth. Premier Health Group, Inc. (PHGRF) (PHGI) is focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry.

  • InvestorPlace5 days ago

    If Small Businesses Start Crumbling, Shopify Stock Is Too Vulnerable

    Underlying Shopify stock is an attractive, and fast-growing business. Indeed, I’ve laid out the bull case for SHOP in the past. After explosive gains from an IPO price of just $17, Shopify stock has settled into a wide range from $120 to $170 over the past ten months.

  • Why Canopy Growth’s Losses Widened in the Second Quarter
    Market Realist5 days ago

    Why Canopy Growth’s Losses Widened in the Second Quarter

    During the second quarter, Canopy Growth’s (WEED) (CGC) operating losses widened from ~$1 million to almost $214 million. The company reported a net loss of $330 million, which widened from losses of $1.6 million a year ago in 2017.